Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML (Leukemia, (2021), 35, 7, (2119-2124), 10.1038/s41375-021-01125-4)

Abstract

In Supplementary Table 2, the n numbers for the response-evaluable patients with higher-risk MDS were swapped for the pevonedistat + azacitidine arm and the azacitidine alone arm. Instead of n=30 and n=29 as originally published, these have now been corrected to n=29 for pevonedistat + azacitidine and n=30 for azacitidine. No changes were required to the response rate percentages as these were calculated using the correct denominators. The updated files are attached to this correction.